S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Reflecting its potent inhibition of serotonin (5-HT) reuptake (accompanying paper), S33005 blocked spontaneous tail-flicks induced by parachloroamphetamine in rats. This action was mimicked by the 5-HT reuptake inhibitor, citalopram, and the 5-HT/norepinephrine (NE) reuptake inhibitor, venlafaxine, whereas the preferential NE reuptake inhibitor, reboxetine, was inactive. Consistent with its less potent interaction with NE transporters, higher doses of S33005 attenuated induction of hypothermia by reserpine, an action mimicked by reboxetine and venlafaxine, whereas citalopram was ineffective. In mice, S33005 reduced immobility in forced-swim and tail-suspension procedures. It also inhibited marble-burying behavior and suppressed aggressive behavior between resident and intruder animals. In rats, S33005 generalized to a discriminative stimulus elicited by citalopram and attenuated hypnotic-sedative actions of the alpha2-adrenoceptor agonist, S18616. For these parameters, S33005 was a more potent agent (median, 1.2 mg/kg, s.c.) than venlafaxine, citalopram, reboxetine, or the tricyclic agent, clomipramine. Even at markedly higher doses (40.0-80.0 mg/kg, s.c.), S33005 little affected motor behavior. S33005 (10.0 mg/kg, s.c.) also increased responses in a learned helplessness paradigm in rats, whereas venlafaxine was ineffective. Finally, in a rat chronic mild-stress model, S33005 dose- (2.5-40.0 mg/kg) and time- (2-5 weeks) dependently enhanced sucrose consumption. Venlafaxine was likewise active in this procedure. In conclusion, in line with its inhibition of 5-HT and (less potently) NE reuptake, S33005 is active in a broad range of models suggestive of antidepressant activity. It exerts its actions more potently than venlafaxine and clomipramine, and its overall profile is distinct from those of citalopram and reboxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 3×
“Anhedonia associated with chronic mild stress involves a perturbation of activity at mesolimbic D2 receptors (Papp et al., 1994; Willner, 1997).”
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302
Sánchez, C., & Meier, E. (1997) · Psychopharmacology · doi:10.1007/s002130050181 · Cited by 255
Redrobe, J. P., Bourin, M., Colombel, M. C., & Baker, G. B. (1998) · Psychopharmacology · doi:10.1007/s002130050638 · Cited by 163
Cited by
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Self-citationAntoniuk, S., Bijata, M., Ponimaskin, E., & Wlodarczyk, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.002 · Cited by 750
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Self-citationDefensive burying in rodents: ethology, neurobiology and psychopharmacology
De Boer, S. F., & Koolhaas, J. M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01278-0 · Cited by 389
Metadata
- Authors
- Millan, M. J., Dekeyne, A., Papp, M., Rochelle, C. D. L., MacSweeny, C., Peglion, J.-L., & Brocco, M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 298
- Issue
- 2
- Pages
- 581-591
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2110914350
- Cited by
- 117
- References
- 4
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29416-7
- The paper
- Millan, M. J., Dekeyne, A., Papp, M., Rochelle, C. D. L., MacSweeny, C., Peglion, J.-L., & Brocco, M. (2001). S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29416-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.